Among them, cdc25A was localised predominantly in the cell nuclei in 29 carcinomas (27.6%) (Figure 2B) and three adenomas (50%), in the cytoplasms in 66 carcinomas (62.9%) (Figure 2A) and two adenomas (33.3%), and in the remaining 10 carcinomas (9.5%) and one adenoma (16.7%) (Figure 2C), it was expressed both in the nuclei and cytoplasms in similar incidences. Here, CDC25A is linked to carcinoma.